This inventor holds 2 USPTO granted patents. Top assignee: Astellas Pharma Gmbh. Active years: 2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006
Title: The Innovations of Takuma Morita
Introduction
Takuma Morita is a notable inventor based in Tsukuba, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on triazole derivatives. With a total of 2 patents, Morita's inventions aim to address critical health issues.
Latest Patents
Morita's latest patents focus on a triazole derivative that inhibits glycine transporter activity. This invention is intended for use as a pharmaceutical drug, showcasing excellent efficacy in treating conditions such as dementia, schizophrenia, and cognitive disorders. The triazole derivative is particularly beneficial for patients suffering from various diseases, including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. Additionally, it addresses spasms associated with nerve degenerative diseases and cerebrovascular disorders. The pharmaceutical drug is especially useful for ameliorating learning disabilities related to dementia.
Career Highlights
Takuma Morita is currently employed at Astellas Pharma GmbH, where he continues to develop innovative solutions in the pharmaceutical industry. His work is characterized by a commitment to improving therapeutic options for patients with cognitive and neurological disorders.
Collaborations
Morita collaborates with esteemed colleagues such as Takahiko Tobe and Takashi Sugane, contributing to a dynamic research environment that fosters innovation.
Conclusion
In summary, Takuma Morita's contributions to the field of pharmaceuticals through his innovative triazole derivatives highlight his dedication to addressing significant health challenges. His work not only advances medical science but also offers hope for patients suffering from debilitating conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
